Stock 600056 CHINA MEHECO GROUP CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials China Meheco Group Co., Ltd.

Equities

600056

CNE000000Q29

Pharmaceuticals

End-of-day quote Shanghai S.E.
Other stock markets
 06:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
10.98 CNY +0.73% Intraday chart for China Meheco Group Co., Ltd. -1.79% -1.70%
Feb. 20 Meheco's Unit Gets Nod to Raise Specifications for Piperacillin Sodium for Injection MT
Feb. 20 Argatroban Injection of Meheco's Subsidiary Passes Chinese Drug Regulator's Evaluation MT

Valuation

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Capitalization 1 26,595 13,431 13,944 15,311 12,619 25,774
Enterprise Value (EV) 1 23,927 11,068 15,095 16,227 14,498 26,864
P/E ratio 20.5 x 8.7 x 14.2 x 11.7 x 19.5 x 35 x
Yield 1.46% 3.45% 2.11% 2.57% 1.54% 0.86%
Capitalization / Revenue 0.88 x 0.43 x 0.4 x 0.39 x 0.35 x 0.69 x
EV / Revenue 0.79 x 0.36 x 0.43 x 0.41 x 0.4 x 0.71 x
EV / EBITDA 11.7 x 5.3 x 7.28 x 5.68 x 9.21 x 16 x
EV / FCF 35.6 x 24.6 x -23 x 13.9 x 51.8 x 34.4 x
FCF Yield 2.81% 4.06% -4.34% 7.22% 1.93% 2.91%
Price to Book 3.43 x 1.59 x 1.55 x 1.53 x 1.23 x 2.38 x
Nbr of stocks (in thousands) 1,495,880 1,495,880 1,495,880 1,495,880 1,495,880 1,495,880
Reference price 2 17.78 8.979 9.321 10.24 8.436 17.23
Announcement Date 3/30/18 3/27/19 4/21/20 4/28/21 4/29/22 4/28/23
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net sales 1 30,102 31,006 35,285 39,312 36,234 37,593
EBITDA 1 2,040 2,087 2,073 2,857 1,574 1,683
EBIT 1 1,862 1,881 1,855 2,642 1,375 1,418
Operating Margin 6.19% 6.07% 5.26% 6.72% 3.8% 3.77%
Earnings before Tax (EBT) 1 1,998 2,333 1,693 1,925 940.1 1,196
Net income 1 1,299 1,545 981.3 1,311 647.1 735.7
Net margin 4.31% 4.98% 2.78% 3.33% 1.79% 1.96%
EPS 2 0.8681 1.032 0.6560 0.8761 0.4326 0.4918
Free Cash Flow 1 671.6 449.1 -654.9 1,171 280.1 781.9
FCF margin 2.23% 1.45% -1.86% 2.98% 0.77% 2.08%
FCF Conversion (EBITDA) 32.92% 21.51% - 40.99% 17.79% 46.47%
FCF Conversion (Net income) 51.72% 29.07% - 89.36% 43.29% 106.28%
Dividend per Share 2 0.2604 0.3098 0.1968 0.2629 0.1298 0.1476
Announcement Date 3/30/18 3/27/19 4/21/20 4/28/21 4/29/22 4/28/23
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net Debt 1 - - 1,151 916 1,880 1,090
Net Cash position 1 2,667 2,362 - - - -
Leverage (Debt/EBITDA) - - 0.5555 x 0.3206 x 1.194 x 0.6476 x
Free Cash Flow 1 672 449 -655 1,171 280 782
ROE (net income / shareholders' equity) 18.4% 18.9% 11.9% 11.9% 5.78% 6.91%
ROA (Net income/ Total Assets) 5.68% 5.02% 4.2% 5.24% 2.67% 2.65%
Assets 1 22,880 30,772 23,358 25,008 24,200 27,815
Book Value Per Share 2 5.190 5.650 6.010 6.690 6.860 7.230
Cash Flow per Share 2 2.230 2.490 1.780 2.380 1.870 2.850
Capex 1 109 262 280 318 286 229
Capex / Sales 0.36% 0.84% 0.79% 0.81% 0.79% 0.61%
Announcement Date 3/30/18 3/27/19 4/21/20 4/28/21 4/29/22 4/28/23
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Pharmaceuticals Wholesale

1st Jan change Capi.
CHINA MEHECO GROUP CO., LTD. Stock China Meheco Group Co., Ltd.
-1.70% 2.27B
MCKESSON CORPORATION Stock McKesson Corporation
+17.35% 71.39B
SINOPHARM GROUP CO. LTD. Stock Sinopharm Group Co. Ltd.
+5.38% 8.59B
SHANGHAI PHARMACEUTICALS HOLDING CO., LTD Stock Shanghai Pharmaceuticals Holding Co., Ltd
+6.69% 8.19B
HUADONG MEDICINE CO., LTD Stock Huadong Medicine Co., Ltd
-20.96% 7.91B
H. LUNDBECK A/S Stock H. Lundbeck A/S
+0.49% 4.54B
JOINTOWN PHARMACEUTICAL GROUP CO., LTD Stock Jointown Pharmaceutical Group Co., Ltd
+17.12% 4.31B
EBOS GROUP LIMITED Stock EBOS Group Limited
-3.38% 3.93B
GALENICA AG Stock Galenica AG
-2.61% 3.86B
CHINA NATIONAL MEDICINES CORPORATION LTD. Stock China National Medicines Corporation Ltd.
+22.08% 3.64B
Pharmaceuticals Wholesale
  1. Stock Market
  2. Equities
  3. 600056 Stock
  4. Financials China Meheco Group Co., Ltd.